Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects

NCT02879877 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT02879877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02879877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Subject-blind, Investigator-blind, Randomized, Placebo-controlled, First-in-human Study Evaluating the Safety/Tolerability, Pharmacokinetics, Effect on Transglutaminase 2 Expression, and Occupancy of Single Ascending Intravenous and Subcutaneous Doses of UCB7858 in Healthy Subjects
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 1
Overall status
Completed
Start date
July 11, 2016
Completion date
January 31, 2018
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers